Abstract
HAM as a combination of high-dose AraC and mitoxantrone produced 53% complete remissions in patients with refractory AML according to rigid criteria. Its sequential version S-HAM even proved successful in salvage treatment for patients pretreated with HAM. In first line treatment TAD-HAM double induction improved the long term remission rate by more than 10% over that following conventional induction. As part of postremission therapy one single course of S-HAM given after TAD consolidation exhibited an antileukemic long term effect equivalent to that from prolonged maintenance treatment. With 38% long-term disease-free survival on the basis of intent to treat in patients < 60 years S-HAM ranges among the most effective intensification regimens.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Büchner T, Hiddemann W, Löffler H, et al. (1994) Double induction in AML comparing high with standard dose Ara-C. Hematotoxicity and anti-leukemic efficacy. Blood 84 (suppl 1): 232a
Bishop JF, Matthews JP,Young GA, et al. (1996) A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 87: 1710–1717
Büchner T, Urbanitz D, Hiddemann W, et al. (1985) Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol, 3: 1583–1589
Mayer RJ, Davis RB, Schiffer CA, et al. (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med, 331: 896–942
Willemze R, Zwaan FE, Colpin G, et al. (1982) High-dose cytosine arabinoside in the management of refractory acute leukemia. Scand J Haematol 29: 414
Estey EH, Keating MJ, McCredie KB, et al. (1983) Phase II trial of mitoxantrone in refractory acute leukemia. Cancer Treat Rep 67: 389
Büchner Th, Barlogie B,Asseburg U, et al. (1974) Accumulation of S-phase cells in the bone marrow of patients with acute leukemia by cytosine arabinoside. Blut 28: 299
Hiddemann W, Kreutzmann H, Straif, K et al. (1987) High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia. Blood 69: 744–749
Hiddemann W, Fonatsch C, Wörmann B, et al. (1995) Cytogenetic subgroups of AML and outcome from high dose versus conventional dose ARA-C as part of double induction therapy. Blood 86 (suppl 1): 267a
Capizzi RL,Yang JI, Cheng E, et al. (1983) Alteration of the pharmacokinetics of high-dose Ara-C by its metabolite, high Ara-U in patients with acute leukemia. J Clin Oncol 1: 763–771
Burke PJ, Karp JE, Braine HG, et al. (1977) Timed sequential therapy of human leukemias based upon the response of leukemic cells to humoral growth factors. Cancer Res 37: 2138–2146
Kern W, Schleyer E, Unterhalt M, et al. (1997) High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias: results of a clinical phase II study. Cancer 79: 59–68
Büchner Th, Hiddemann W, Wörmann B, et al. (1996) Intensive consolidation versus prolonged maintenance following intensive induction and conventional consolidation in primary AML: a study by AMLCG. Blood 88 (suppl 1): 214a
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Büchner, T. et al. (1998). Intensified Therapy for AML:The Role of the HAM Combination. In: Hiddemann, W., et al. Acute Leukemias VII. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 39. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71960-8_110
Download citation
DOI: https://doi.org/10.1007/978-3-642-71960-8_110
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-71962-2
Online ISBN: 978-3-642-71960-8
eBook Packages: Springer Book Archive